Cold atmospheric plasma in cancer therapy

  • Michael Keidar
    George Washington University 1 Mechanical and Aerospace Engineering, , Washington DC 20052, USA
  • Alex Shashurin
    George Washington University 1 Mechanical and Aerospace Engineering, , Washington DC 20052, USA
  • Olga Volotskova
    George Washington University 1 Mechanical and Aerospace Engineering, , Washington DC 20052, USA
  • Mary Ann Stepp
    George Washington University 2 Medical School, , Washington DC 20052, USA
  • Priya Srinivasan
    Childrens National Medical Center 3 , Washington DC 20010, USA
  • Anthony Sandler
    Childrens National Medical Center 3 , Washington DC 20010, USA
  • Barry Trink
    Johns Hopkins University 4 Head and Neck Cancer Research Division, Department of Otolaryngology, School of Medicine, , Baltimore, Maryland 21205, USA

説明

<jats:p>Recent progress in atmospheric plasmas has led to the creation of cold plasmas with ion temperature close to room temperature. This paper outlines recent progress in understanding of cold plasma physics as well as application of cold atmospheric plasma (CAP) in cancer therapy. Varieties of novel plasma diagnostic techniques were developed recently in a quest to understand physics of CAP. It was established that the streamer head charge is about 108 electrons, the electrical field in the head vicinity is about 107 V/m, and the electron density of the streamer column is about 1019 m−3. Both in-vitro and in-vivo studies of CAP action on cancer were performed. It was shown that the cold plasma application selectively eradicates cancer cells in-vitro without damaging normal cells and significantly reduces tumor size in-vivo. Studies indicate that the mechanism of action of cold plasma on cancer cells is related to generation of reactive oxygen species with possible induction of the apoptosis pathway. It is also shown that the cancer cells are more susceptible to the effects of CAP because a greater percentage of cells are in the S phase of the cell cycle.</jats:p>

収録刊行物

被引用文献 (34)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ